Loading...
Docoh

Maravai LifeSciences (MRVI)

Maravai LifeSciences enables the development of drug therapies, diagnostics and novel vaccines and supports research on human diseases through its portfolio of market-leading companies and proprietary technologies. Maravai companies are global leaders in providing products and services into the fields of nucleic acid production, biologics safety testing, and protein detection to many of the world's leading biopharma, vaccine, diagnostics, and cell and gene therapy companies.

Company profile

Ticker
MRVI
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
Maravai Topco Holdings, LLC • Maravai Intermediate Holdings, LLC • TriLink Biotechnologies, LLC • Glen Research, LLC • MockV Solutions, Inc. • Cygnus Technologies, LLC • MyChem, LLC ...

MRVI stock data

Analyst ratings and price targets

Last 3 months

Calendar

5 Aug 22
28 Sep 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
My notes
No notes yet
My annotations
No annotations yet

Community content

Community notes
No notes yet
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Jul 22 Peter Michael Leddy Class A Common Stock Grant Acquire A No No 0 63,498 0 63,498
15 Jul 22 Peter Michael Leddy Employee Stock Option Class A Common Stock Grant Acquire A No No 24.94 122,893 3.06M 122,893
29 Apr 22 Kurt Oreshack Class A Common Stock Grant Acquire A No No 22.95 394 9.04K 25,931
29 Apr 22 Christine Dolan Class A Common Stock Grant Acquire A No No 22.95 666 15.28K 18,785
29 Apr 22 Kevin Herde Class A Common Stock Grant Acquire A No No 22.95 427 9.8K 20,816
13F holders Current Prev Q Change
Total holders 211 230 -8.3%
Opened positions 23 50 -54.0%
Closed positions 42 46 -8.7%
Increased positions 89 78 +14.1%
Reduced positions 74 77 -3.9%
13F shares Current Prev Q Change
Total value 9.78B 10.57B -7.4%
Total shares 275.39M 272.26M +1.1%
Total puts 86.4K 88.1K -1.9%
Total calls 218.1K 337.1K -35.3%
Total put/call ratio 0.4 0.3 +51.6%
Largest owners Shares Value Change
Maravai Life Sciences Holdings 2 145.35M $6.09B 0.0%
GTCR 21.68M $615.96M 0.0%
Select Equity 19.11M $543.06M +0.1%
Massachusetts Financial Services 12.69M $360.56M +41.6%
Vanguard 10.43M $296.4M -0.8%
BLK Blackrock 5.81M $165.07M -2.9%
Ownership Capital B.V. 4.39M $124.78M +4.4%
FMR 4.01M $113.87M -57.5%
JPM JPMorgan Chase & Co. 3.53M $100.3M +4.0%
MS Morgan Stanley 2.84M $80.55M -0.3%
Largest transactions Shares Bought/sold Change
FMR 4.01M -5.43M -57.5%
Massachusetts Financial Services 12.69M +3.73M +41.6%
American Century Companies 2.4M +2.4M NEW
Champlain Investment Partners 2.42M -1.16M -32.4%
Natixis 0 -1M EXIT
Renaissance Technologies 1.88M +961.8K +105.3%
Artemis Investment Management 2.23M +918.96K +69.9%
PRU Prudential Financial 1.24M +737.31K +147.5%
Millennium Management 109.25K -555.43K -83.6%
Aqr Capital Management 593.14K +441.49K +291.1%

Financial report summary

?
Risks
  • Risks Related to Our Business and Strategy
  • Certain of our products are used by customers in the production of vaccines and therapies, some of which represent relatively new and still-developing modes of treatment. Unforeseen adverse events, negative clinical outcomes, or increased regulatory scrutiny of these and their financial cost may damage public perception of the safety, utility, or efficacy of these vaccines and therapies or other modes of treatment and may harm our customers’ ability to conduct their business. Such events may negatively impact our revenue and have an adverse effect on our performance.
  • A pandemic, epidemic, or outbreak of an infectious disease, such as COVID-19, has affected, and may continue to affect our business, financial condition, results of operations, cash flows and prospects.
  • Changes in economic conditions could negatively impact our revenue and earnings.
  • We are dependent on our customers’ spending on and demand for outsourced nucleic acid production amd biologics safety testing products and services. A reduction in spending or demand could have a material adverse effect on our business, financial condition, results of operations, cash flows and prospects.
  • We compete with life science, pharmaceutical and biotechnology companies who are substantially larger than we are and potentially capable of developing new approaches that could make our products, services and technology obsolete.
  • If our products and services do not perform as expected or the reliability of the technology on which our products and services are based is questioned, we could experience lost revenue, delayed or reduced market acceptance of our products and services, increased costs and damage to our reputation.
  • Our products are highly complex and are subject to quality control requirements.
  • Until the 2020 fiscal year, we had incurred losses for each fiscal year since inception, we may incur losses in the future and we may not be able to generate sufficient revenue to maintain profitability.
  • Our operating results may fluctuate significantly in the future, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.
  • If we are unable to manufacture in specific quantities, our operating results will be harmed.
  • Natural disasters, geopolitical unrest, war, terrorism, public health issues or other catastrophic events could disrupt the supply, delivery or demand of products and services, as well as our sites, which could negatively affect our operations and performance.
  • Strategic transactions or acquisitions may require us to seek additional financing, which we may not be able to secure on favorable terms, if at all.
  • If we are unable to continue to hire and retain skilled personnel, we will have trouble developing and marketing our products and services.
  • Our success depends on the market acceptance of our life science reagents. Our reagents may not achieve or maintain significant commercial market acceptance.
  • The market may not be receptive to our new products and services upon their introduction.
  • It may be difficult for us to implement our strategies for revenue growth in light of competitive challenges.
  • Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the market in which we compete achieves the forecasted growth, our business could fail to grow at similar rates, if at all.
  • Product liability lawsuits against us could cause us to incur substantial liabilities, limit sales of our existing products and limit commercialization of any products that we may develop.
  • We may be unable to efficiently manage growth as a larger and more geographically diverse organization.
  • Opportunistic acquisitions may pose risks and challenges that could adversely affect our business, and we may not achieve the anticipated benefits of acquisitions of businesses or technologies.
  • Our ability to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments is limited by provisions of the Internal Revenue Code, and it is possible that certain transactions or a combination of certain transactions may result in material additional limitations on our ability to use our net operating loss and tax credit carryforwards.
  • We may be required to record a significant charge to earnings if our goodwill and other amortizable intangible assets, or other investments become impaired.
  • Changes in accounting principles and guidance could result in unfavorable accounting charges or effects.
  • Our revenue recognition and other factors may impact our financial results in any given period and make them difficult to predict.
  • Fluctuations in our effective tax rate may adversely affect our results of operations and cash flows.
  • Our business is subject to a number of environmental risks.
  • Risks Related to Our Reliance on Third Parties
  • We depend on a limited number of customers for a high percentage of our revenue. If we cannot maintain our current relationships with customers, fail to sustain recurring sources of revenue with our existing customers, or if we fail to enter into new relationships, our future operating results will be adversely affected.
  • We may enter into additional distribution arrangements and marketing alliances for certain products and services and any failure to successfully identify and implement these arrangements on favorable terms, if at all, may impair our ability to effectively distribute and market our products.
  • We rely on a limited number of suppliers or, in some cases, sole suppliers, for some of our raw materials and may not be able to find replacements or immediately transition to alternative suppliers.
  • We depend on a stable and adequate supply of quality raw materials from our suppliers, and price increases or interruptions of such supply could have an adverse impact on our business, financial condition, results of operations, cash flows and prospects.
  • Because we rely heavily on third-party package-delivery services, a significant disruption in these services, damages or losses sustained during shipping or significant increases in prices could adversely affect our business, financial condition, results of operations, cash flows and prospects.
  • Our products could become subject to more onerous regulation by the FDA or other regulatory agencies in the future, which could increase our costs and delay or prevent commercialization of our products, thereby materially and adversely affecting our business, financial condition, results of operations, cash flows and prospects.
  • We are subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies and contractual obligations could adversely affect our business, financial condition, results of operations, cash flows and prospects.
  • We are subject to export and import control laws and regulations that could impair our ability to compete in international markets or subject us to liability if we violate such laws and regulations.
  • Changes in political, economic or governmental regulations may reduce demand for our products and services or increase our expenses.
  • We are subject to financial, operating, legal and compliance risk associated with global operations.
  • Our activities are and will continue to be subject to extensive government regulation, which is expensive and time consuming.
  • Increasing scrutiny and changing expectations from investors, lenders, customers, government regulators and other market participants with respect to our Environmental, Social and Governance (“ESG”) policies and activities may impose additional costs on us or expose us to additional risks.
  • Risks Related to Our Intellectual Property and Technology
  • If we are unable to obtain, maintain and enforce intellectual property protection for our current or future products, or if the scope of our intellectual property protection is not sufficiently broad, our ability to commercialize our products successfully and to compete effectively may be materially adversely affected.
  • Our internal computer systems, or those of our customers, collaborators or other contractors, have been and may in the future be subject to cyber-attacks or security breaches, which could result in a material disruption of our product development programs or otherwise adversely affect our business, financial condition, results of operations, cash flows and prospects.
  • If we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be materially adversely affected.
  • We may become involved in lawsuits to protect or enforce our patents, which could be expensive, time-consuming and unsuccessful and could result in a court or administrative body finding our patents to be invalid or unenforceable.
  • If we are sued for infringing, misappropriating, or otherwise violating intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our current or future products.
  • Intellectual property litigation and other proceedings could cause us to spend substantial resources and distract our personnel from their normal responsibilities.
  • If we fail to comply with our obligations under any license agreements, disagree over contract interpretation, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are necessary to our business.
  • Changes to the patent law in the United States and other jurisdictions could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, thereby impairing our ability to protect our technologies and current or future products.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.
  • We may be subject to claims by third parties asserting that our employees, consultants, independent contractors or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property and proprietary technology.
  • We may not be able to protect our intellectual property and proprietary rights throughout the world.
  • We rely on confidentiality agreements that, if breached, may be difficult to enforce and could have a material adverse effect on our business and competitive position.
  • If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business, financial condition, results of operations, cash flows and prospects may be adversely affected.
  • Intellectual property rights do not necessarily address all potential threats.
  • Risks Related to Our Indebtedness
  • Our existing indebtedness could adversely affect our business and growth prospects.
  • Despite current indebtedness levels, we may incur substantially more indebtedness, which could further exacerbate the risks associated with our substantial indebtedness.
  • Variable rate indebtedness that we have incurred or may in the future incur will subject us to interest rate risk, which could cause our debt service obligations to increase significantly.
  • We may not be able to generate sufficient cash flow to service all of our indebtedness and may be forced to take other actions to satisfy our obligations under such indebtedness, which may not be successful.
  • The terms of the financing documents governing our Credit Agreement restrict our current and future operations, particularly our ability to respond to changes or to take certain actions.
  • We may be unable to refinance our indebtedness.
  • Our failure to raise additional capital or generate cash flows necessary to expand our operations and invest in new technologies in the future could reduce our ability to compete successfully and harm our competitive position and results of operations.
  • Risks Related to Our Organizational Structure
  • Our principal asset is our interest in Maravai Topco Holdings LLC (“Topco LLC”), and, accordingly, we depend on distributions from Topco LLC to pay our taxes and expenses, including payments under the Tax Receivable Agreement. Topco LLC’s ability to make such distributions may be subject to various limitations and restrictions.
  • Conflicts of interest could arise between our shareholders and Maravai Life Sciences Holdings, LLC (“MLSH 1”), which may impede business decisions that could benefit our shareholders.
  • The Tax Receivable Agreement requires us to make cash payments to MLSH 1 and MLSH 2 in respect of certain tax benefits to which we may become entitled, and we expect that the payments we will be required to make will be substantial.
  • The amounts that we may be required to pay to MLSH 1 and MLSH 2 under the Tax Receivable Agreement may be accelerated in certain circumstances and may also significantly exceed the actual tax benefits that we ultimately realize.
  • Our organizational structure, including the Tax Receivable Agreement, confers certain benefits upon MLSH 1 and MLSH 2 that will not benefit the other common shareholders to the same extent as they will benefit MLSH 1 and MLSH 2.
  • We may not be able to realize all or a portion of the tax benefits that are currently expected to result from the tax attributes covered by the Tax Receivable Agreement and from payments made under the Tax Receivable Agreement.
  • In certain circumstances, Topco LLC will be required to make distributions to us and MLSH 1 and the distributions may be substantial.
  • Unanticipated changes in effective tax rates or adverse outcomes resulting from examination of our income or other tax returns could adversely affect our operating results and financial condition.
  • If we were deemed to be an investment company under the Investment Company Act of 1940, as amended (the “1940 Act”), applicable restrictions could make it impractical for us to continue our business as contemplated and could have a material adverse effect on our business, financial condition, results of operations, cash flows and prospects.
  • Risks Related to Being a Public Company
  • We are obligated to develop and maintain proper and effective internal control over financial reporting in order to comply with Section 404 of the Sarbanes-Oxley Act. We may not complete our analysis of our internal control over financial reporting in a timely manner, or these internal controls may not be determined to be operating effectively, which may adversely affect investor confidence in us and, as a result, the value of our Class A common stock.
  • The requirements of being a public company may strain our resources and distract our management, which could make it difficult to manage our business, particularly now that we are no longer an “emerging growth company.”
  • Risks Related to Our Class A Common Stock
  • GTCR controls us, and its interests may conflict with ours or yours in the future.
  • We are a “controlled company” within the meaning of the rules of NASDAQ and, as a result, we qualify for and rely on exemptions from certain corporate governance requirements. You will not have the same protections as those afforded to shareholders of companies that are subject to such governance requirements.
  • Provisions of our corporate governance documents could make an acquisition of us more difficult and may prevent attempts by our shareholders to replace or remove our current management, even if beneficial to our shareholders.
  • Our certificate of incorporation designates the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation that may be initiated by our shareholders and the federal district courts of the United States as the exclusive forum for litigation arising under the Securities Act, which could limit our shareholders’ ability to obtain a favorable judicial forum for disputes with us.
  • Our operating results and stock price may be volatile.
  • A significant portion of our total outstanding shares of Class A common stock, including newly issued shares of Class A common stock issued upon the exchange of UP-C interests by MLSH 1, may be sold into the market in the near future. This could cause the market price of our Class A common stock to drop significantly, even if our business is doing well.
  • Because we have no current plans to pay regular cash dividends on our Class A common, you may not receive any return on investment unless you sell your Class A common stock for a price greater than that which you paid for it.
  • We may issue shares of preferred stock in the future, which could make it difficult for another company to acquire us or could otherwise adversely affect holders of our Class A common stock, which could depress the price of our Class A common stock.
Management Discussion
  • The results of operations presented below should be reviewed in conjunction with the condensed consolidated financial statements and notes included elsewhere in this Quarterly Report on Form 10-Q. For information with respect to recent
  • accounting pronouncements that are of significance or potential significance to us, see Note 1 to the condensed consolidated financial statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q.
  • *As adjusted to reflect the impact of the adoption of ASC 842. See Note 1 to the condensed consolidated financial statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q for a summary of the adjustments.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: adding, augment, BARDA, behalf, cleanroom, cooperative, countermeasure, coverage, declared, Department, developmental, eligible, evidenced, highest, Joint, lab, lessor, light, medical, molecule, Nuclear, predicated, priority, Radiological, reaching, recaptured, reciprocal, reconcile, refund, thereof, validation, warehouse
Removed: column, created, deep, disruption, leveraging, positively, responded, robust

Patents

Utility
Compositions and Methods for Synthesizing 5'-CAPPED Rnas
15 Sep 22
Provided herein are methods and compositions for synthesizing 5′Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2′Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.
Utility
Compositions and methods for synthesizing 5′-capped RNAs
16 Aug 22
Provided herein are methods and compositions for synthesizing 5′Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2′Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.
Utility
Immunofluorescence Assays
24 Feb 22
Provided herein are immunofluorescence assays that do not use an intensely colored lipophilic dye, and that result in a significant reduction of fluorescence due to aldehyde fixation, collagen, elastin, and/or red blood cells.
Utility
Compositions and Methods for Synthesizing 5'-CAPPED Rnas
2 Dec 21
Provided herein are methods and compositions for synthesizing 5′Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7Gppp[N2′Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.
Utility
Compositions and Methods for Synthesizing 5'-CAPPED Rnas
26 Aug 21
Provided herein are methods and compositions for synthesizing 5′Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7 Gppp[N2′Ome]n[N]m wherein m7G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.